The economic benefits of acetylcholinesterase inhibitors for patients with Alzheimer disease and associated dementias

Alzheimer Disease and Associated Disorders
H M Fillit, Jerrold Hill

Abstract

Most cost-effectiveness studies using simulation modeling have demonstrated that donepezil, rivastigmine, and galantamine are cost effective for the treatment of mild-to-moderate Alzheimer disease (AD). These conclusions are in large part based on the assumption that improvement in cognitive status, or prevention of cognitive and functional decline, reduces the amount of time patients spend institutionalized or receiving other full-time care. However, as discussed in this article, outcomes besides delay to institutionalization affect the costs of AD. In reviews of utilization data from Medicare and managed care organizations, it was noted that hospitalization and post acute care in skilled nursing facilities accounted for the largest amount of excess direct costs, even among patients with mild or moderate AD. These utilization reviews also suggest that many patients with AD and related dementias require inpatient care because they are not able to self-manage comorbid conditions. The improvements in cognitive status and daily functioning associated with acetylcholinesterase inhibitor (AChEI) therapy are expected to translate into improved management of comorbidities and reduced caregiver burden, thus reducing the total cost of c...Continue Reading

References

Jan 1, 1992·International Psychogeriatrics·L TorianH Fillit
Aug 1, 1994·American Journal of Public Health·R L Ernst, J W Hay
May 1, 1997·Health Affairs·P FishmanJ Hecht
Jun 1, 1997·Archives of Neurology·R L ErnstJ A Yesavage
Jun 13, 1998·Journal of the American Geriatrics Society·M WeinerG F Anderson
Aug 8, 1998·International Journal of Geriatric Psychiatry·A StewartG Dempsey
Sep 16, 1998·Clinical Therapeutics·G W SmallR L Brooks
Jan 23, 1999·Health Affairs·J LeonP J Neumann
Mar 8, 1998·PharmacoEconomics·A Briggs, M Sculpher
May 14, 1999·Journal of the American Geriatrics Society·B J O'BrienS Gauthier
Jun 11, 1999·The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences·S M AlbertY Stern
Jun 16, 1999·Alzheimer Disease and Associated Disorders·N W Kowall
Aug 14, 1999·Journal of Geriatric Psychiatry and Neurology·M Trabucchi
Sep 14, 1999·Journal of the American Geriatrics Society·E M GuttermanH Fillit
Jan 25, 2000·Clinical Therapeutics·H FillitB Lewis
Jun 16, 2000·Journal of the American Geriatrics Society·D H Taylor, F A Sloan
Sep 20, 2000·Alzheimer Disease and Associated Disorders·L JönssonB Winblad
Apr 17, 2001·PharmacoEconomics·H M Lamb, K L Goa
Aug 28, 2001·The Journals of Gerontology. Series B, Psychological Sciences and Social Sciences·D H TaylorF A Sloan
Oct 19, 2001·Journal of Neurology, Neurosurgery, and Psychiatry·K RockwoodD Wilkinson
Dec 4, 2001·Dementia and Geriatric Cognitive Disorders·Shunya IkedaNaoki Ikegami
Feb 28, 2002·The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences·P Murali DoraiswamyPeter J Neumann
May 8, 2002·International Journal of Geriatric Psychiatry·Michal Schnaider BeeriShlomo Noy
May 25, 2002·Journal of the American Geriatrics Society·Gary W SmallGeorge Papadopoulos
Jun 1, 2002·Alzheimer Disease and Associated Disorders·Michal Schnaider BeeriShlomo Noy
Jul 2, 2002·The British Journal of Psychiatry : the Journal of Mental Science·J WolstenholmeT Hope
Jul 30, 2002·Dementia and Geriatric Cognitive Disorders·J Jaime CaroUNKNOWN AHEAD Study Group. Assessment of Health Economics in Alzheimer's Disease
Jul 16, 2003·Clinical Therapeutics·Kristen Migliaccio-WalleUNKNOWN AHEAD Study Group

❮ Previous
Next ❯

Citations

Jul 22, 2005·Lancet Neurology·Chengxuan QiuLaura Fratiglioni
May 15, 2008·Archives of Cardiovascular Diseases·E Duron, O Hanon
Nov 2, 2011·Canadian Journal on Aging = La Revue Canadienne Du Vieillissement·Paul StoleeKenneth Rockwood
Jan 1, 2008·Patient Preference and Adherence·Susan M Abughosh, Stephen J Kogut
Nov 19, 2010·Annals of Indian Academy of Neurology·Ashok JaiswalN D Kantharia
Apr 15, 2014·General Hospital Psychiatry·B H Green, E C Griffiths
Jun 5, 2012·La Revue de médecine interne·M ChaariI Elalamy
May 13, 2011·American Journal of Alzheimer's Disease and Other Dementias·Josephine Mauskopf, Lisa Mucha
Nov 15, 2017·Journal of Occupational and Environmental Medicine·Marta FarréAdelaida Zabalegui
Sep 24, 2015·The Cochrane Database of Systematic Reviews·Jacqueline S BirksJohn Grimley Evans
Aug 22, 2009·Journal of the American Geriatrics Society·W David CrewsCulvette M Kunze
Sep 1, 2005·Irish Journal of Psychological Medicine·Sharon Foley, Aideen Freyne

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

The British Journal of Psychiatry : the Journal of Mental Science
Paul Lelliott, Bernard Audini
The British Journal of Psychiatry : the Journal of Mental Science
Gyles GloverKannan Suresh Babu
Health Affairs
Steven S Sharfstein, Faith B Dickerson
© 2022 Meta ULC. All rights reserved